


































Cell proliferation is controlled by cytokines including 
growth factors and the components of extracellular 
matrix. Both types of proteins initiate signal 
transduction through growth factor specific receptors 
and matrix-specific receptors integrins, and their 
disbalance may lead to the uncontrolled proliferation 
and carcinogenesis [1-4].  Different integrins can 
interact with the same matrix proteins thus generating 
physiologically similar signals [5] making evaluation of 
the functional impact of individual integrins a 
cumbersome task. 
 
The fibronectin-binding α5β1 is the only integrin with 
the single ligand specificity and yet, it often exerts 
controversial effects on cell proliferation and 
carcinogenesis ranging from stimulatory to inhibitory 
[6-10]. The mechanisms underlying the regulation of 
cell proliferation by integrins have not  been  completely  
 
 

































characterized.  One such mechanism includes 
interaction between integrins and growth factor 
receptors, GFR, with subsequent modification of GFR 
activity [2,11].  It has been shown that the outcome of 
these interactions varies in different cell types, and 
depends on growth conditions.  For example, in  
human epidermoid carcinoma HEp3 cells, α5 integrin 
binding to the  epidermal growth factor receptor, EGFR, 
enhanced proliferation [10] while in Caco-2 and  HT-29 
colorectal carcinoma cells, α5/EGFR binding resulted 
in EGFR lysosomal degradation  followed by 
proliferation arrest [ 6].  
 
Alternatively, integrins may control cell fate via 
regulation of apoptosis, specifically anoikis, an 
anchorage-dependent apoptosis [12].   Intriguingly, the 
role of α5β1 integrin in regulation of anoikis appears to 
be controversial.  In particular, up-regulation of α5β1 
was essential for survival of MCF-10 breast carcinoma 
cells devoid of ECM substrate [13] whereas in human 
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mediated resistance to anoikis  entirely depended on 
suppression of α5β1 integrin [8]. Therefore, studies 
addressing the role of individual integrins in different 
cell types are important for understanding the receptor-
mediated regulation of mitogenic mechanisms in these 
cell types. 
 
In the present study, we investigated the role of α5β1 
integrin in proliferation of epidermoid carcinoma cells. 
We demonstrated that α5β1 regulates proliferation of 
these cells via twofold mechanism: by stimulating 
EGFR signaling cascade and by maintaining activated 
state of Akt kinase that is required for continuous 




 Down-regulation of α5β1 expression or inhibition of 
EGFR activity evokes similar effects on A431 cell 
proliferation but differ in regulation of cell survival   
 
Synergistic effects on the mitotic activity of growth 
factor receptors, in particular EGFR, and integrins have 
been reported previously [2, 6, 11].  To elucidate the 
mechanisms of such synergy, we compared the effects 
on the proliferation of A431 cells of down-regulation of 
α5β1 and suppression of EGFR-mediated signaling.  To 
this end, the kinase activity of EGFR was inhibited by 
commercially available inhibitor PD168393.  The α5β1 
-mediated signaling was attenuated using siRNA 
technology.  As shown in Figure 1, two different α5-
specific shRNAs substantially decreased the amounts of 
α5 as was determined by immunoblotting or by 
detection of α5β1 expression on the cell surface using 
FACS-based technology.   Down-regulation of α5β1 
levels or inhibition of EGFR activity exerted similar 
negative effects on proliferation of A431 cell (Figure 
2А-C).  Statistically significant difference between the 
control and experimental groups was detected as soon 
as in 48 hrs.  To further delineate inhibitory effects of 
a5β1 knockdown or EGFR inhibition, we performed 
analysis of the cell cycle progression using PI-based 
FACS. As shown in Figure 3, treatment with the EGFR 
inhibitor increased accumulation of cells in the G1-
phase of the cell cycle and at the same time decreased 
their accumulation in the S- and G2/M-phases.   
Importantly, no cells with the sub-G1 amounts of DNA 
(a hallmark of the apoptotic DNA degradation) were 
detected in PD168393-treated cells.  Thus, EGFR 
inhibition caused the G1 cell cycle arrest but no 
apoptosis.  Interestingly,  a5β1 knock-down resulted in 
the G1 cell cycle arrest 48 hours after infection with 
shRNAs  and in substantial apoptosis starting 72 hours 
after infection that was evident by a significant increase 
of the sub-G1 population of cells. Тherefore, inhibition 
of EGFR signaling led to the G1 proliferation arrest, 
whereas a5β1 knock-down resulted in the G1 cell cycle 








































The cell cycle analysis data were confirmed by 
assessing expression of the proliferation and apoptosis 
markers in studied cell populations (Figure 4).   Upon 
inhibition of EGFR or α5β1, expression levels of c-Myc 
decreased, whereas the active form of p53 and the 
cyclin dependent kinase inhibitor p27 increased.  In 
contrast, inhibition of α5β1 but not EGFR resulted in 
activation of caspases 3 and 9 which correlated with the 
emergence of the sub-G1 peak in cells depleted of  α5 







probed  with  1:1000  dilution  of  polyclonal α 5  antibody  and
1:500 dilution of β‐actin mAb, stained using ECL system and
scanned. (B and C) Flow cytometry of the cells tranduced with

























































Signaling pathways that mediate effects caused by 
inhibition of α5β1 and EGFR   
 
Next,  we  investigated  possible  common  downstream  
signaling pathways for α5β1 and EGFR.  We 
demonstrated that down-regulation of α5β1 or 
inhibition of EGFR activity substantially affected 
phosphorylation of focal adhesion kinase FAK at  Tyr 
925 (Figure 5A),  that was reported previously to be 
required for FAK activity [14] .  It has been shown that 
FAK co-localizes and physically associates with 
integrins at focal contacts and serves as an early sensor 
of integrin signaling [15]. The fact that inhibition of 
both α5β1 and EGFR led to the dramatic decrease of 
active FAK suggests that this enzyme is the primary 














































suppress  proliferation  of  A431  cells.  (A  and  B)  Cells
tranduced with control or α5 shRNA  vectors were cultivated in
serum‐reduced  medium  for  24  h  and  seeded  as  described  in
“Materials  and  methods”.  (C)  Cells  were  cultivated  in‐serum
reduced  medium  for  24  h,  treated  with  5  μM  of  the  EGFR
inhibitor,  PD168393,  at  37
0C  for  1  h,  seeded  in  complete
medium for 24‐72 h and quantified as described in “Materials
and  method”.  Control  (untreated)  samples  contaned  0,5%
DMSO.  Shown  are  the  mean  ±  SD  of  two  independent
experiments.  
Figure 3. Integrin α5 knock‐down and inhibition of EGFR
exert  different  yet  overlapping  effects  on  cell  cycle
distribution of A431 cells.  Cells  treated  with  PD168393  as
detailed in Fig. 2 (A) or transduced with control or α5  shRNA‐
containing vectors (B) were seeded for 48‐72 h, then fixed  and
prepared  for  flow  cytometry  as  indicated  in  “Materials  and
methods”.  FACS  analysis  was  performed  on  a  FACS‐Calibur
(Bekton Dickinson). Shown are typical experiments. 
   

































Phosphatidylinositol-3-kinase (PI3K)/Akt and mitogen 
activated protein kinases (MAP), in particular, Erk, are 
known to transduce integrin signals [2]. Previously, we 
have demonstrated that α5β1 inhibition in the breast 
carcinoma cells caused a decrease in the activity of Akt 
and Erk2 [16].  We confirmed these effects in A431 
cells (Fig.5А), however, unlike a5β1 knock-down, 
attenuation of EGFR activity had no effect on the 
amount of active Akt, whereas the activity of Erk1 and 
Erk2  decreased.  To reveal whether this discrepancy 
accounts for the difference in cellular phenotypes 
induced by inhibition of α5β1 and EGFR, we tested the 
effects of Akt inhibitor LY294002 and MAP kinase 
inhibitor PD98059 on A431 cell proliferation. Figure 
5B demonstrates that both treatments profoundly 
inhibited proliferation of these cells. These data are in 
line with highly reduced proliferation of various cancer 
cell lines resulted from the down-regulation of  of 
PI3K/Akt signaling [1, 4]  Importantly, unlike 
PD98059, prolonged treatment with LY294002 (up to 
48 hours) induced significant apoptosis in A431 cells as 
was evident by FACS analysis (Figure 5C).  Critical 
role of Akt in cell  protection from apoptosis has been 
























































regulators  in  A431  cells.  The  cells  were  transduced  with
control  or  α5  shRNA‐containing  vectors  or  treated  with
PD168393 (as detailed in “Materials and methods” and Fig. 2)
then  western  blot  analysis  and  ECL‐staining  were  performed.
The blots were probed with 1:300 dulution of c‐Myc antibodies
and with 1:1000 dilution of other antibodies. 




antibodies.  (B)  Inhibition  of  Akt  and  Erk1/2  lead  to  a  strongly 
reduced  proliferation  of  A431  cells.  Cells  were  incubated  in 
serum‐reduced  medium,  containing  25  μM  of  PI‐3K  inhibitor 
LY294002 (Sigma) or Erk inhibitor PD98059 (Calbiochem) or 0,5% 





analysis  was  performed  on  a  FACS‐Calibur  (Bekton  Dickinson). 
Shown are typical experiments. 
   
www.impactaging.com                  371                                              AGING, May 2012, Vol.4 No.5To verify whether decreased expression of a5β1 
partially or completely abolishes activation of EGFR, 
we studied phosphoryaltion status of EGFR at Tyr1086 
or Tyr1148 in A431 cells depleted of α5.  
Phosphorylation at Tyr 1086 mediates matrix-activated 
α5β1 signaling whereas phosphorylation at Tyr 1148 
occurs in response to epidermal growth factor [19,  20].  
We demonstrated that indeed down-regulation of α5β1 
caused significant decrease of both phosphorylated 
forms of EGFR (Figure 6A). Furthermore, we 
demonstrated that α5β1 and EGFR can be co-
immunoprecipitated with anti-α5 antibodies (Figure 6B) 
thus suggesting physical interactions between these 








































The role of α5β1 integrin in regulation of proliferation 
of normal and malignant cells is controversial. The 
expression of α5β1 was higher in proliferating retinal 
cells than in their quiescent counterparts [ 9]. Activation 
of α5β1 by its ligand fibronectin enhanced proliferation 
of cultured endothelium of lymphoid vessels [21]. 
Furthermore, growth rates of preadipocytes increased 
after the exogenous expression of α5β1 [22].  Likewise, 
the specific inhibitor of α5β1, JSM6427, caused 
retardation of proliferation of glioma [23] and 
endothelial [24] cells.  On the other hand, inhibitory 
effects of α5β1 on cell proliferation have also been 
reported.  Overexpression of α5β1 in Caco-2 and HT-
29 colon cancer cells with low endogenous levels of this 
integrin abrogated their tumorigenicity [6]. 
Accordingly, it has been suggested that the inhibitory 
effects of tocopherol (vitamin E) on glioma cell 
proliferation were associated with higher expression of 
α5β1 [7].   It is conceivable that one of the reasons for 
these discrepancies is the cell type specific mechanisms 
of α5β1 signaling. Therefore, a detailed characterization 
of  α5β1-mediated pathways in individual cell types 
emerges as an important question.  
 
The results of our study agree with previous 
observations of growth stimulatory effect of this 
integrin [21-24].  Cooperative signaling between 
integrins and growth factor receptors has been 
demonstrated earlier [20, 25, 26].  Thus, interaction of 
α5β1 with growth factor receptors was shown to occur 
in the presence as well as in the absence of growth 
factors [19]. In Caco-2 intestinal epithelium cell line 
that lacks α5β1 the exogenous expression of this 
integrin induced cell proliferation, and this effect can be 
attenuated by the antibody that blocks EGFR activity 
[27].  These results are in line with our data that showed 
the decreased phosphorylation of FAK and Erk as a 
result of inhibition of α5β1 and EGFR signaling. These 
data are further corroborated by a dramatic decrease of 
two active phopshorylated forms of EGFR in cells with 
down-regulated α5β1 аnd by formation of complexes 
between α5β1 and EGFR (Figure 6). 
 
Another mechanism of α5β1-mediated control of cell 
proliferation is associated with integrin-dependent 
maintenance of pro-survival signaling via continuous 
activation of Akt, a known suppressor of apoptosis.  Data 
in Figures 3, 4 and 5 strongly suggest that α5β1 signaling 
is required for maintaining anti-apoptosis signaling in 
studied cells.  In contrast, EGFR signaling in these cells 




activity  of  EGFR  in  A431  cells.  (A)  The  cells  were
transduced  with  α5  shRNA  or  treated  with  PD168393  as
described above followed by western‐blot analysis. The blots
were  probed  with  1:1000  dilution  of  EGFR  and  pEGFR
antibodies and 1:500 dilution of anti‐β‐actin mAb. (B) Integrin
α5 interacts with EGFR. Co‐immunoprecipitation of EGFR with
integrin  α5.  A  1  mg  aliquat  of  cell  extracts  obtained  from
intact A431 cells was immunoprecipitated with 5 μl of  the
human  α5β1  mAb  (MAB  1999,  Chemicon).  The  precipitates
were  run  on  SDS‐PAGE  and  western  blotted  with  the
polyclonal antibodies to α5 subunit and EGFR. As a control,
cell lysate proteins (30 μg) were resolved and western blotted
with  the  α5  and  EGFR  antibodies.  Control
immunoprecipitation  with  an  α5β1  isotype  specific  IgG  is
shown. 
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of Akt blocked α5β1-mediated pro-survival signaling in 
serum-deprived endothelial cells however, inhibition of 
MAPK had no effect on integrin-dependent anti-
apoptosis [21]. 
 
  In summary, our results suggest that α5β1 integrin 
regulates cell proliferation by at least two signaling 
mechanisms: maintaining pro-survival Akt-dependent 
signaling and activation of  EGFR.  
 
MATERIALS AND METHODS       
 
Cell culture and chemicals.  A431 human epidermoid 
carcinoma cell line was obtained from ATCC. Cells 
were cultured in DMEM supplemented with 10% fetal 
calf serum (HyClone, USA), 2 mM glutamine, 100 
U/ml penicillin, and 100 μg/ml streptomycin, and 
incubated in a humidified incubator with 5% СО2 at 37
0 
C. Erk and EGFR inhibitors, PD98059 and PD168393, 
resp, were purchased from Calbiochem (CA, USA), and 
other chemicals were obtained from Sigma (MO, USA). 
 
Lentiviral shRNA constructs. Bacterial glycerol stocks 
[clones NM_002205.1-2595s1c1 (#53) and 
NM_002205.1-1178s1c1 (#49) containing lentivirus 
plasmid vector pLKO.1-puro with shRNA specific for 
a5 integrin subunit was purchased from Sigma (MO, 





pLKO.1-puro lentiviral vector without shRNA was used 
as a control. Lentiviruses were produced in HEK293T 
cells after co-transfection of lentivirus plasmid vector 
with shRNA or control vector with packaging plasmids 
using ExGen 500 Transfection Reagent (Fermentas).   
After 72 h medium containing lentivirus was collected 
and filtered through 0.45 uM filter. Filtered virus 
containing medium was used for cell infection. Cells 
were transduced with lentivirus in the presence of 8 
mg/ml polybrene and selected with puromycin (1,0 
mg/ml) for 4 days.  
 
Cell proliferation assay. Cells were cultivated for 24 h 
in serum-reduced medium and then seeded in DMEM 
supplemented with 10% serum at a density of  10
4 
cells/well into 48-well cell culture plates. After distinct 
time intervals, the cells were harvested and quantified 
using MTT-test. 
 
Cell cycle analysis. 10
6 cells were fixed with ice-cold 
70% ethanol, resuspended in 1.0 ml solution of 40 
μg/ml  DNase-free RNase A in PBS and incubated for 
30 min at room temperature. Propidium iodide was 
added to a fnal concentration of  20 μg/ml and cells 
were stored for 3 h on ice. Cell cycle analysis was 
performed by flow cytometry (FACS Calibur, BD) 
using WinMDI 2.8 software. 
 
Imunoblotting and immunoprecipitation. The following 
antibodies were used: anti-α5β1 integrin mAb and anti-
α5 subunit polyclonal antibodies from Chemicon, anti-
c-Myc mAb and anti-β-actin mAb from Santa Cruz 
Biotechnology; anti-p27 from BD; monoclonal 
antibodies to phospho-EGFR (Tyr1086/Tyr158), 
phospho-FAK (Tyr925), phospho-Akt (Ser473), 
phospho-Erk1/2 (Thr202/Thr204), c-Myc, caspase-3, 
caspase-9, phospho-p53 (Ser15) as well as polyclonal 
antibodies against EGFR, FAK, p53 were from Cell 
Signaling. Cells were extracted with RIPA buffer (1% 
Triton X-100 in 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0,5% DOX, 0.1% SDS), containing protease 
inhibitor cocktail (Sigma) and phosphatase inhibitor 
cocktail (Santa Cruz Biotech), each 1μl/10
6 cells, and 
centrifuged at 13000 g for 10 min. 30 μg of cell lysate 
proteins were run on 7.5% SDS-PAGE under reducing 
conditions. 
 
For immunoprecipitation experiments, 0.5 - 1 mg of 
proteins were immunoprecipitated with the appropriate 
antibody for 1 h at 4
0C in the presence of 25 μl of 
protein A/G agarose (Amersham). Following SDS-
PAGE, proteins were electroblotted onto a PVDF 
membrane. After reaction with specific primary 
antibodies the membrane was incubated with HRP-
conjugated secondary antibodies, developed in ECL 
detection system (Amersham) and scanned.  
 
Statistical analysis. Statistical significance was 
determined with Student’s test comparison between two 
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